Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07246161

Vaginal Detection of Orally Delivered Probiotic Strains in Healthy Women

The purpose of the present study is to obtain more information on the transit of orally ingested probiotics to the vagina.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Evalulab

Montreal, Canada

Location status: Recruiting

Location contact

Evalulab

CONTACT

514-434-0001

About this study

Probiotics have emerged as novel supplements to support women's health, demonstrating benefits in maintain vaginal health and promoting recovery from dysbiosis. This includes various oral and vaginal probiotics shown to alleviate symptoms and enhance the reversal of vaginal dysbiosis.

Oral delivered probiotic strains suggest their ability to migrate and transiently colonize the vagina to support vaginal health but is not well understood. Therefore, this study will aim to provide additional information on their transit to the vagina.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinically healthy female between the ages of 18 and 50 years, inclusive,
  • have a regular or predictable menstrual cycle
  • Typically have regular bowel movements,
  • Willing and able to consume a probiotic supplement for 4 weeks,
  • Willing to discontinue consumption of probiotic supplement and probiotic-fortified products 2 weeks before the start of the study and throughout the study,
  • Willing to discontinue fiber supplements 2 weeks before the start of the study, and throughout the study,
  • Willing to provide 1 stool sample 4 times throughout the study,
  • Willing to provide 2 vaginal swabs 4 times throughout the study,
  • Willing to undergo vaginal pH swab measurements (with a swab) 5 times throughout the study,
  • Willing to provide 2 perineal skin swabs (skin between the vagina and the anus) 3 times throughout the study,
  • Willing to complete a pregnancy test at the screening visit.

Exclusion criteria

  • Menopausal women,
  • Vaginal pH < 2 or > 5 measured at screening,

•. Menstruation during the sample collection times,

  • Women that are lactating, pregnant, attempting to get pregnant, or have a positive pregnancy test,
  • Use of vaginal probiotics in the last 3 months,
  • Use of local vaginal antibiotics or antifungals in the last 3 months.
  • Use of oral antibiotics or antifungals in the last month,
  • Ongoing symptoms of vaginal and/or urinary tract infections,
  • Current treatment for vaginal sepsis or urosepsis,
  • Currently being treated for a severe chronic disease (e.g. cancer, renal failure, chronic inflammatory digestive or gastro-intestinal disease, immunodeficiency, etc.),
  • Clinical diagnosis of a gynecological disease or condition (e.g, fibroma, endometriosis, polycystic ovarian syndrome, etc.),
  • Clinical diagnosis of secondary dysmenorrhea,
  • Intolerance, allergy or sensitivity to milk, soy, or yeast.

Treatment and study plan

Probiotic Formula 1

Other

Probiotic Formula 1

Probiotic Formula 2

Other

Probiotic Formula 2

Probiotic Formula 3

Other

Probiotic Formula 3

Primary outcomes

  1. Presence or absence of probiotic stains in vaginal swabs after 28 days of oral intake

    Time frame: 28 days of oral intake

Secondary outcomes

  1. Presence or absence of the probiotic stains in the vaginal swabs at days 0 & 14 of oral intake, and 1 week after the end of intervention (Day 35)

    Time frame: From enrollment to day 35

  2. Presence or absence of the probiotic strains in perineal skin swabs at days 0, 14, and 28 of oral intake.

    Time frame: From enrollment to the 28th day.

  3. Presence or absence of the probiotic strains in stool samples at days 0, 14 and 28 of oral intake.

    Time frame: From enrollment to 28th day

  4. Viability of the probiotic strains recovered from vaginal swabs at days 0, 14, and 28 of oral intake, and 1 week after the end of the intervention (Day 35)

    Time frame: From enrollment to the 35th day.

  5. Viability of the probiotic strains recovered from perineal skin swabs at day 0, 14, and 28 of oral intake.

    Time frame: From enrollment to 28th day

  6. Changes in vaginal pH from baseline to 1 week after the end of the intervention (Day 35)

    Time frame: From baseline to day 35.

  7. Changes in the abundance of endogenous and pathogenic bacterial and fungal species in the vagina at days 0, 14, 28 and 35.

    Time frame: From enrollment to the 35th day

Other outcomes

  1. Number of adverse events (AEs) and serious adverse events (SAEs) reported throughout the study.

    Time frame: From enrollment to the 35th day

Study contacts

Contact information is provided by the study sponsor or research team.

Jenna Bouassaly, MSc

CONTACT

[email protected]

514-223-2057

Sponsors and collaborators

Lead sponsor

Lallemand Health Solutions

Industry

Registry information

Official study title

Detection of Orally Delivered Probiotic Strains in the Vaginal Microbiome of Healthy Female Adults

Acronym: VSS2

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 24, 2025
Registry last updated
Jun 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.